Fig. 7

WT and Gsdmd^−/− BMDM EV profiling. A Experimental paradigm showcasing in-vitro inflammasome activation of BMDM. B IL-1β release from WT and Gsdmd^−/− BMDM post-LPS/ATP stimulation, as measured by ELISA (p < 0.05, N = 4). C EV concentration measured using nanoparticle tracking analysis (NTA) was significantly reduced in the supernatant of BMDM from Gsdmd^−/− mice compared to WT controls, following stimulation with LPS/ATP (p < 0.05, N = 4–6). This effect was also seen following 24 h of recovery (p < 0.05, N = 4–6). D EV mean and mode size (in nm) measured using NTA showing no change in mean size (p > 0.05, N = 4–6) but shift in mode size (p < 0.05, N = 4–6) at 24-h recovery timepoint. This shift in size is reflected in E BMDM EV profiles showing size distribution data obtained from NTA. There is no change in EV profiles in untreated condition (i) or 4.5-h post-LPS/ATP stimulation (ii), however, there is a shift in profile at 24-h recovery timepoint (iii). F, G EV IL-1β release from WT and Gsdmd^−/− BMDM post-LPS/ATP stimulation, as measured by ELISA (p < 0.05, N = 4)